The Effects of MDCO-2010, a Serine Protease Inhibitor, on Activated Clotting Time in Blood Obtained from Volunteers and Cardiac Surgical Patients | Zendy

Heezoo Kim | Zendy; Fania Szlam | Zendy; Kenichi A. Tanaka | Zendy; Andreas van de Locht | Zendy; Satoru Ogawa | Zendy; Jerrold H. Levy | Zendy

Open Access

The Effects of MDCO-2010, a Serine Protease Inhibitor, on Activated Clotting Time in Blood Obtained from Volunteers and Cardiac Surgical Patients

Author(s) -

Heezoo Kim,

Fania Szlam,

Kenichi A. Tanaka,

Andreas van de Locht,

Satoru Ogawa,

Jerrold H. Levy

Publication year - 2012

Publication title -

anesthesia and analgesia

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.404

H-Index - 201

eISSN - 1526-7598

pISSN - 0003-2999

DOI - 10.1213/ane.0b013e3182576a5a

Subject(s) - activated clotting time , medicine , aprotinin , partial thromboplastin time , heparin , prothrombin time , clotting time , anesthesia , thrombin time , fibrinogen , serine protease , surgery , coagulation , protease , biochemistry , chemistry , enzyme

The activated clotting time (ACT) is widely used for monitoring heparin anticoagulation during cardiac surgery. Celite-based ACT values are prolonged when aprotinin is administered. MDCO-2010, a novel serine protease inhibitor, is currently being evaluated as a possible alternative to aprotinin. Therefore, we evaluated the in vitro effects of this novel agent on ACT values using 3 different point-of-care instruments with kaolin or celite as an activator.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research